Masuda A, Mais D E, Oatis J E, Halushka P V
Department of Pharmacology, Medical University of South Carolina, Charleston 29425.
Biochem Pharmacol. 1991 Jul 15;42(3):537-44. doi: 10.1016/0006-2952(91)90316-w.
Thromboxane A2 (TXA2) and its precursor prostaglandin H2 (PGH2) induce platelet aggregation and vascular contraction through shared cell surface receptors commonly referred to as TXA2 or TXA2/PGH2 receptors. Whether different subclasses of TXA2/PGH2 receptors exist in platelets and vascular smooth muscle cells is controversial. In this study, TXA2 receptors on washed rat and human platelets and cultured rat aortic smooth muscle cells (RASMC) were characterized using radioligand competition binding assays with the 125I-labeled TXA2/PGH2 receptor agonist [1S-(1 alpha,2 beta(5Z),3 alpha(1E,3R*),4 alpha)] -7- [3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl) -7- oxabicyclo-[2.2.1]- heptan-2-yl] -5- heptenoic acid (I-BOP) and various agonists and antagonists. Scatchard analyses of equilibrium binding data revealed Kd values of 205 +/- 68 pM (N = 6), 2.2 +/- 0.3 nM (N = 9) and 310 +/- 60 pM (N = 7) and Bmax values of 1.3 +/- 0.45 fmol/10(6) platelets, 2.8 +/- 0.2 fmol/10(6) platelets and 20.9 +/- 2.2 fmol/10(6) cells for rat and human platelets and RASMC, respectively. Concentration-dependent increases in intracellular free Ca2+ concentrations induced by I-BOP were observed in RASMC loaded with the calcium sensitive dye fura-2. The IC50 values for various TXA2/PGH2 analogues in competition binding assays with 125I-BOP were determined. Based on their IC50 values, the rank orders were I-BOP less than L657925 less than ONO11113 less than or equal to SQ29548 less than PTA-TPO less than PTA-NO less than or equal to L657926 less than or equal to I-PTA-OH less than PTA-OH[2] = meta-I-PTA-PO less than or equal to ONO11120[2] = ONO11120[1] less than PTA-OH[1] in rat platelets. I-BOP less than SQ29548 less than PTA-TPO = L657925 less than or equal to ONO11113 less than I-PTA-OH less than PTA-NO less than or equal to meta-I-PTA-PO less than or equal to PTA-OH[2] less than ONO11120[2] less than or equal to ONO11120[1] less than L657926 less than or equal to PTA-OH[1] in human platelets, and I-BOP less than L657925 less than ONO11113 less than or equal to SQ29548 less than ONO11120[2] less than or equal to L657926 less than or equal to PTA-OH[2] less than PTA-TPO less than ONO11120[1] less than I-PTA-OH less than meta-I-PTA-PO less than PTA-NO less than PTA-OH[1] in RASMC.(ABSTRACT TRUNCATED AT 400 WORDS)
血栓素A2(TXA2)及其前体前列腺素H2(PGH2)通过通常被称为TXA2或TXA2/PGH2受体的共同细胞表面受体诱导血小板聚集和血管收缩。血小板和血管平滑肌细胞中是否存在不同亚类的TXA2/PGH2受体存在争议。在本研究中,使用放射性配体竞争结合试验,以125I标记的TXA2/PGH2受体激动剂[1S-(1α,2β(5Z),3α(1E,3R*),4α)] -7- [3-(3-羟基-4-(4'-碘苯氧基)-1-丁烯基) -7- 氧杂双环-[2.2.1]-庚烷-2-基] -5-庚烯酸(I-BOP)以及各种激动剂和拮抗剂,对洗涤后的大鼠和人血小板以及培养的大鼠主动脉平滑肌细胞(RASMC)上的TXA2受体进行了表征。对平衡结合数据的Scatchard分析显示,大鼠和人血小板以及RASMC的Kd值分别为205±68 pM(N = 6)、2.2±0.3 nM(N = 9)和310±60 pM(N = 7),Bmax值分别为1.3±0.45 fmol/10(6)个血小板、2.8±0.2 fmol/10(6)个血小板和20.9±2.2 fmol/10(6)个细胞。在用钙敏感染料fura-2负载的RASMC中观察到I-BOP诱导的细胞内游离Ca2+浓度的浓度依赖性增加。测定了各种TXA2/PGH2类似物在与125I-BOP竞争结合试验中的IC50值。根据它们的IC50值,在大鼠血小板中的排序为I-BOP<L657925<ONO11113≤SQ2954<PTA-TPO<PTA-NO≤L657926≤I-PTA-OH<PTA-OH[2]=间位-I-PTA-PO≤ONO11120[2]=ONO11120[1]<PTA-OH[1]。在人血小板中为I-BOP<SQ29548<PTA-TPO = L657925≤ONO11113<I-PTA-OH<PTA-NO≤间位-I-PTA-PO≤PTA-OH[2]<ONO11120[2]≤ONO11120[1]<L657926≤PTA-OH[1],在RASMC中为I-BOP<L657925<ONO11113≤SQ29548<ONO11120[2]≤L657926≤PTA-OH[2]<PTA-TPO<ONO11120[1]<I-PTA-OH<间位-I-PTA-PO<PTA-NO<PTA-OH[1]。(摘要截短至400字)